Truncated IL-21 Peptides for Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-21 variants have limitations in terms of activity, selectivity, stability, and biological half-life, necessitating the development of improved variants with enhanced binding to the IL-21 receptor for therapeutic applications.
Innovation Solution
The development of IL-21 peptides with reduced or replaced regions corresponding to specific amino acid residues (e.g., 66 to 98, 77 to 92, 83 to 86) to maintain or improve activity, combined with the use of nucleic acid constructs and specific antibodies for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the length of amino acid residues 66 to 98 in SEQ ID No. 2 is reduced, then binding activity to IL-21 receptor is improved or maintained, but peptide length is reduced
Solution Approach 1:
The patent extracts and removes specific amino acid residues (66-98, 77-92, 82-88, 71-92, or 65-92) from the IL-21 peptide sequence to create truncated variants. This extraction principle directly resolves the contradiction by removing non-essential regions while preserving the core binding activity to the IL-21 receptor, thereby improving or maintaining reliability while reducing peptide length.
Solution Approach 2:
The patent systematically varies the length parameters of the peptide by deleting different numbers of amino acid residues at specific positions. By changing the length parameter of different regions (13 residues, 16 residues, 6 residues, 21 residues, or 28 residues), the invention identifies optimal truncation points that maintain binding activity while minimizing peptide length, thus resolving the contradiction between reliability and length.
2Reliability
If IL-21 variants are developed to improve binding activity, then selectivity is improved, but complexity of variant development increases
Solution Approach 1:
The patent segments the IL-21 peptide into functional regions by identifying and removing specific amino acid stretches (66-98, 77-92, 82-88, etc.). This segmentation approach allows systematic evaluation of different truncated variants, improving selectivity through targeted modifications while managing complexity through a structured, modular approach to variant development.
Data Source
AI summary
IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98.